Abstract

Background: The burden of chronic kidney disease (CKD) is rising globally. CKD is often associated with multiple comorbidities which pose the risk of mortality and morbidity and are responsible for disease progression affecting the individuals’ quality of life. In order to slow the disease progression and treat the multiple comorbidities, patients with CKD are often faced with polypharmacy which is one of the leading problems in renal medicine as it is associated with potential drug-drug interactions, greater healthcare costs, and low medication adherence. This study assesses the current medication therapy in CKD to understand polypharmacy, the curresnt prescribing patterns, and the potential drug-drug interactions. Additionally, the quality of life in CKD patients has also been assessed.